Video and resources: https://multiplesclerosisacademy.org/2020/07/16/webinar-siponimod-how-do-we-give-patients-with-secondary-progressive-ms-hope/

In June 2020, NICE issued draft guidance which saying it was unable to recommend siponimod as a disease modifying drug (DMD) for secondary progressive MS (SPMS) in England and Wales. 

The news came as a blow to people with SPMS who have no other treatment options, and to clinicians who had been discussing the possibility of the drug with their patients.

Dr David Paling, Prof Gavin Giovannoni, and Dr Rachel Farrell discussed the implications of the decision and the future of SPMS treatment.

10 July 2020
Please note that all session and slide content are the views of the Speakers, not the MS Academy. The content of the recording is the speaker’s personal opinion at the time of recording. Due to the everchanging situation, advice given at the time of recording is subject to change.

This meeting has been sponsored by Roche Products Limited. Roche Products Limited has had no control over the educational content of this activity.

Siponimod – how do we give patients with secondary progressive MS hope?

The Neurology Academy is an innovative training programme helping you to hone your expertise within our Academy specialities. 
We are an education provider for clinicians, specialist nurses and professions allied to medicine and the training focus is on both disease management and service transformation.